PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Sohail Rao, MD,MA,DPhil
- Phone Number: 956-362-2387
- Email: s.rao@dhr-rgv.com
Study Contact Backup
- Name: Monica Betancourt-Garcia, MD
- Phone Number: 956-362-3223
- Email: m.betancourt@dhr-rgv.com
Study Locations
-
-
Texas
-
Brownsville, Texas, United States, 78521
- Recruiting
- Brownsville Independent School District
-
Contact:
- Monica Betancourt-Garcia, MD
- Phone Number: 956-362-3223
- Email: m.betancourt@dhr-rgv.com
-
Contact:
- Sohail Rao, MD, MA, DPhil
- Phone Number: 956-362-2387
- Email: s.rao@dhr-rgv.com
-
Edinburg, Texas, United States, 78539
- Recruiting
- DHR Health Institute for Research and Development
-
Contact:
- Sohail Rao, MD,MA,DPhil
- Phone Number: 956-362-2387
- Email: s.rao@dhr-rgv.com
-
Contact:
- Monica Betancourt-Garcia, MD
- Phone Number: 956-362-3223
- Email: m.betancourt@dhr-rgv.com
-
Edinburg, Texas, United States, 78542
- Recruiting
- Edinburg CISD School Based Health Center
-
Contact:
- Monica Betancourt-Garcia, MD
- Phone Number: 956-362-3223
- Email: m.betancourt@dhr-rgv.com
-
Contact:
- Sohail Rao, MD,MA, DPhil
- Phone Number: 956-362-2387
- Email: s.rao@dhr-rgv.com
-
Rio Grande City, Texas, United States, 78582
- Recruiting
- Starr County Memorial Hospital
-
Contact:
- Monica Betancourt-Garcia, MD
- Phone Number: 956-362-3223
- Email: m.betancourt@dhr-rgv.com
-
Contact:
- Sohail Rao, MD, MA, DPhil
- Phone Number: 956-362-2387
- Email: s.rao@dhr-rgv.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults 18 years and over that have been fully vaccinated (2 doses) with the Pfizer/BioNTech COVID-19 vaccine (BNT162b2) and with the 1st booster at least 90 days prior to the 2nd booster
- Healthcare workers employed by and/or affiliated with DHR Health, Renaissance Medical Foundation, DHR Partners, Starr County Memorial Hospital
- Any adult with any of the following risk factors for severe COVID-19 disease progression (as outlined by the CDC)
Exclusion Criteria:
- Previous history of allergic reaction to vaccination
- less than or equal to 3 months from last booster dose of vaccine
- active SARS-COV-2 infection
- less than or equal to 21 days of full recovery from SARS-CoV-2 infection
- less than or equal to 14 days of any vaccination
- vaccinated with any other available COVID-19 vaccine other than Pfizer/BioNTech or Moderna
- Healthcare workers not employed by and/or affiliated with DHR Health, Renaissance Medical Foundation, Star County Memorial Hospital or non DHR Partners
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Administration of Booster Dose
study participant will receive either 30ug in 0.3 ml of Pfizer/BioNTech (BNT162b2) or 0.25 ml of Moderna vaccine administered intramuscularly.
|
participants will receive a booster dose (1st booster or 2nd booster) of vaccine
participants will receive a booster dose (1st booster or 2nd booster) of vaccine
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants infected with SARS-CoV-2 after booster Dose
Time Frame: 24 months
|
Determine effectiveness of booster dose in the prevention of SARS-CoV-2 Infection by assessing if subjects remain free from infections with SARS-CoV-2 after receiving booster dose.
|
24 months
|
|
Levels of anti-SARS-CoV-2 IgG antibody titers after booster
Time Frame: 24 months
|
Determine the anti-SARS-CoV-2 IgG antibody titers using a semi quantitative method at various time points (Baseline/Day 0, Day 14, Week 12 and Week 24 after booster) to assess for sustained levels of relatively high titers of anti-SARS-CoV-2 IgG in the blood of the subjects
|
24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measure rate of decline of immune responses
Time Frame: 24 months
|
Determine the rate of decline of immune responses in various cohort of recipients with similar co-morbidities by conducting cohort analysis
|
24 months
|
|
Identify differences in immune responses based on comorbidity status
Time Frame: 24 months
|
Identify differences in immune responses based on comorbidity status (e.g., Immune response in recipients with metabolic diseases vs. patients with immunosuppression) by using questionnaires
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sohail Rao, MD,MA,DPhil, DHR Health Institute for Research and Development
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1789039
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.